Singular Bio's mission
Bringing the power of human genome analysis to healthcare screening.
Singular Bio’s testing platform was designed and built specifically to meet the needs of high volume, broad population health care testing. Typically, genetic tests are accurate but very expensive, limiting their use to a small number of high risk individuals. Conversely, most screening tests are inexpensive and broadly offered, but only moderately accurate, so limiting their value in the making clinical decisions.
Expanding access to high quality healthcare
Singular Bio’s approach combines the superior performance of genetic analysis with the low cost and fast turnaround time of screening tests. Singular Bio’s tests can be widely used, enabling early disease detection and reducing unnecessary medical procedures.
Founder and CEO
Previously Hywel was Vice President of Business Development at True Materials, a genetic testing company acquired by Affymetrix. Prior to True Materials, Dr. Jones was Director of Market Development at Affymetrix, focused on novel technologies and applications. Dr. Jones has a PhD in Statistical Genetics from Cambridge University in England and was a visiting fellow at Stanford University where his research focused on detecting genetic variants involved in common, complex disease and their diagnostic application.
Chief Technology Officer
Jim has more than 15 years of experience leading the design and development of genomics analysis tools for research and diagnostic applications. Prior to joining Singular Bio, he directed technical operations at Complete Genomics, a next-generation genome sequencing company, and later was Senior Director, Molecular Biology at CellScape where he developed methods for analysis of fetal cells retrieved from maternal circulation. He earlier led the development of microarray platform technologies and products for use in clinical cytogenetic applications at Agilent and Affymetrix. Dr. Collins has a Ph.D. in Microbiology from University College Cork in Ireland and conducted postdoctoral research at Wageningen University in The Netherlands.
Vice President, Strategy and Business Operations
Prior to joining Singular Bio, she was Director of Archstone Consulting’s Life Sciences practice. In that capacity, Ms. Bergsteinsson advised companies – from large biopharmaceuticals to health tech start-ups – in growth strategies and strategic planning, along with developing and building high-performing teams to achieve her clients’ strategic goals. Ms. Bergsteinsson has a B.S. in Mechanical Engineering from Stanford University and received her MBA in Health Care Management from the Wharton School at the University of Pennsylvania.